Research programme: melanocortin-4 receptor agonists - MotusAlternative Names: BIM 22103
Latest Information Update: 18 Apr 2016
At a glance
- Originator Ipsen
- Developer Ipsen; Motus
- Class Peptides
- Mechanism of Action Melanocortin type 4 receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Obesity